000131878 001__ 131878
000131878 005__ 20250129092438.0
000131878 0247_ $$2DOI$$a10.1038/jcbfm.2012.80
000131878 037__ $$aFZJ-2013-01138
000131878 082__ $$a610
000131878 1001_ $$0P:(DE-HGF)0$$aBecker, G$$b0$$eCorresponding author
000131878 1112_ $$aThe 9th International Symposium on Functional Neuroreceptor Mapping of the Living Brain$$cBaltimore$$d2012-08-09 - 2012-08-11$$gNRM2012$$wUSA
000131878 245__ $$aPET Quantification Of 18F-Flubatine Binding To Nicotinic alpha4beta2 acetylcholine receptors in Human Brains
000131878 260__ $$a[s.l.]$$bOvid$$c2012
000131878 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1360751061_18024
000131878 3367_ $$2DataCite$$aOutput Types/Journal article
000131878 3367_ $$00$$2EndNote$$aJournal Article
000131878 3367_ $$2BibTeX$$aARTICLE
000131878 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131878 3367_ $$2DRIVER$$aarticle
000131878 500__ $$3POF3_Assignment on 2016-02-29
000131878 520__ $$aObjectives: Nicotinic alpha4beta2 acetylcholine receptors (nAChR) are an important target for diagnostic neuroimaging because of their involvement in Alzheimer's disease (AD) and Parkinson's disease. Using 2-[18F]F-A85380 PET a significant decline in alpha4beta2-nAChRs in early AD-patients which correlated to loss of cognitive function was shown (1, 2). However, this tracer is not suited for use as biomarker for early AD-diagnosis in a routine clinical set-up because of its unfavourable slow kinetics. Here we used the new radiotracer (-)-[18F]-Flubatine (formerly (-)-[18F]-NCFHEB) with significantly improved brain uptake, receptor affinity and selectivity (3). nAChR-parameters were determined by full kinetic modeling and the validity of the practically useful tissue ratio and tissue-to-plasma ratio as receptor parameters was evaluated.  Methods: After intravenous administration of ~370 MBq (-)-[18F]-Flubatine, the PET brain imaging was performed in 20 healthy controls (age 70.6±4.6) using an ECAT EXACT HR+ system in 3D-acquisition mode. 23 frames were acquired from 0-90 min post injection and motion corrected with SPM2. Kinetic modeling using a 1-tissue compartment model (1TCM) with arterial input-function was applied to the volume of interest (VOI) based tissue-activity curves (TACs) generated for 29 brain regions (anatomically defined via MRI co-registration). Model-based receptor parameters used were the total distribution volume (VT) and the distribution volume ratio (DVR) (reference: posterior corpus callosum). In addition the standardized uptake value ratio (SUVR) (50-70 min) as approximation of the DVR and the tissue-to-plasma concentration ratio (TTPR) (70-90 min) as approximation of VT were used as non model-based receptor parameters. Results: TACs of all 29 regions could be described adequately with the 1TCM and all kinetic parameters could be reliably estimated from 90 min PET data. VT increased as expected with receptor density. Corpus callosum (VT: 5.68±1.01), frontal cortex (9.18±0.59), parietal cortex (9.10±0.61), pons (11.10±0.86), thalamus (25.03±3.33). Mean TTPR values in frontal and parietal cortices were 2% higher than the corresponding VT values but 7% lower in the thalamus. There was a strong linear correlation between the two sets of TTPR and VT values (r2 = 0.98, p < 10-4) (Fig. 1A). As VT, DVR increased with receptor density. Frontal cortex (DVR: 1.66±0.27), parietal cortex (1.64±0.27), pons (2.01±0.35), thalamus (4.52±0.87). Mean SUVR values in frontal and parietal cortices were almost identical to mean DVR values (difference <0.1%) but ~15 % lower in the thalamus. Accordingly there was a strong linear correlation between the SUVR and DVR values (r2 = 0.97, p < 10-4) (Fig. 1B).  Conclusions: For (-)-[18F]-Flubatine the receptor parameters TTPR and SUVR in cortical regions are in excellent agreement with corresponding parameters computed by full kinetic modeling. For unbiased estimates of TTPR and SUVR in the thalamus the use of a bolus/infusion scheme for tracer application should be considered.  References: 1. O. Sabri, ..P. Brust: Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 2008; 35 (Suppl. 1): 30-45. 2. K. Kendziorra, ..O. Sabri: Decreased cerebral a4ß2 nicotinic acetylcholine receptors in living patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 2010; 38: 515-525. 3. P. Brust, ..O. Sabri: In-vivo measurement of nicotinic acetylcholine receptors with [18 F]norchloro-fluoro-homoepibatidine (NCFHEB). Synapse 2008; 62: 205-218. Linear regression analysis. (A) Tissue-to-plasma concentration ratio (TTPR) and total distribution volume (VT). (B) Standardized uptake value ratio (SUVR) and distribution volume ratio (DVR).
000131878 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000131878 536__ $$0G:(DE-Juel1)BMBF-01EZ0822$$aBMBF-01EZ0822 - NorChloro-Fluoro HomoEpiBatidin (NCFHEB)  ein potentieller Positronen-Emission Tomographie-(PET) Marker der frühen Alzheimer-Demenz (BMBF-01EZ0822)$$cBMBF-01EZ0822$$x1
000131878 7001_ $$0P:(DE-HGF)0$$aWilke, S$$b1
000131878 7001_ $$0P:(DE-HGF)0$$aSchönknecht, P$$b2
000131878 7001_ $$0P:(DE-HGF)0$$aPatt, M$$b3
000131878 7001_ $$0P:(DE-HGF)0$$aLuthardt, J$$b4
000131878 7001_ $$0P:(DE-HGF)0$$aHesse, S$$b5
000131878 7001_ $$0P:(DE-Juel1)133954$$aWagenknecht, Gudrun$$b6
000131878 7001_ $$0P:(DE-HGF)0$$aHöpping, A$$b7
000131878 7001_ $$0P:(DE-HGF)0$$aBrust, P$$b8
000131878 7001_ $$0P:(DE-HGF)0$$aSabri, O$$b9
000131878 773__ $$0PERI:(DE-600)2039456-1$$a10.1038/jcbfm.2012.80$$nS1$$pS. 172-173 (P149)$$tJournal of cerebral blood flow & metabolism$$v32$$x1559-7016
000131878 909CO $$ooai:juser.fz-juelich.de:131878$$pVDB
000131878 9141_ $$y2012
000131878 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000131878 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000131878 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131878 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131878 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131878 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131878 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131878 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131878 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131878 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000131878 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131878 9101_ $$0I:(DE-Juel1)ZEA-2-20090406$$6P:(DE-Juel1)133954$$aZentralinstitut für Elektronik$$b6$$kZEA-2
000131878 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133954$$aForschungszentrum Jülich GmbH$$b6$$kFZJ
000131878 9132_ $$0G:(DE-HGF)POF3-579H$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vAddenda$$x0
000131878 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000131878 9201_ $$0I:(DE-Juel1)ZEL-20090406$$kZEL$$lZentralinstitut für Elektronik$$x0
000131878 9201_ $$0I:(DE-Juel1)ZEA-2-20090406$$kZEA-2$$lZentralinstitut für Elektronik$$x1
000131878 980__ $$ajournal
000131878 980__ $$aVDB
000131878 980__ $$aUNRESTRICTED
000131878 980__ $$aI:(DE-Juel1)ZEL-20090406
000131878 980__ $$aI:(DE-Juel1)ZEA-2-20090406
000131878 981__ $$aI:(DE-Juel1)PGI-4-20110106
000131878 981__ $$aI:(DE-Juel1)ZEA-2-20090406